COLL250117P22500
- 0.60
- 0.000.00%
Collegium Pharmaceutical Newsroom
Pulling Back 6.0% This Week, Collegium Pharmaceutical's NASDAQ:COLL) Three-year Decline in Earnings May Be Coming Into Investors Focus
Despite Lower Earnings Than Three Years Ago, Collegium Pharmaceutical (NASDAQ:COLL) Investors Are up 46% Since Then
Indivior CFO Steps Down From Board After Discussions With Oaktree Capital
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
US Manufacturing Index Rises To 43, Highest Since 2020
Express News | COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Collegium to Participate in Upcoming Investor Conferences
Jefferies Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $40
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
H.C. Wainwright Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $50
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Collegium Pharmaceutical (COLL)
Needham Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Summary
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
Collegium Pharmaceutical Non-GAAP EPS of $1.61 Beats by $0.02, Revenue of $159.3M Beats by $3.73M
Collegium Pharmaceutical: Q3 Earnings Snapshot
Express News | Collegium Pharmaceutical Inc -Reaffirms Its Full-Year 2024 Guidance
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q3 EPS $1.61
Collegium Pharmaceutical | 10-Q: Q3 2024 Earnings Report